ROE of Gilead Sciences Inc. (NASDAQ:GILD) stands at 82.9

Image source Gilead Sciences

The analyst recommendations from a month ago are 1 Buy, 0 Overweight, 0 Sell, 0 Hold and 0 Underweight. Bank of America Corporation reaffirmed a "neutral" rating and issued a $100.00 price target on shares of Gilead Sciences in a research note on Sunday, September 25th.

02/08/2017 - Gilead Sciences, Inc. was downgraded to "buy" by analysts at CFRA Research. 23 Analysts think that the Price Target for Gilead Sciences Inc. The analysts noted that the move was a valuation call. RBC Capital Markets decreased their price objective on shares of Gilead Sciences from $95.00 to $90.00 and set an outperform rating on the stock in a research report on Wednesday, November 2nd. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the company. The company now has an average rating of "Buy" and a consensus target price of $96.85. (NASDAQ:GILD) in which Stifel Nicolaus Initiates Coverage On Gilead Sciences Inc. According to these analysts, the Low Revenue Estimate for Gilead Sciences Inc.is 6.14 Billion and the High Revenue Estimate is 7.1 Billion. The Market Cap of the company stands at 89.03 Billion. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -4.76% where SMA50 and SMA200 are -6.85% and -13.11% respectively.

These analysts also forecasted Growth Estimates for the Current Quarter for GILD to be -25.4%.

Earnings surprise history: Last quarter, the company posted approximately $7.32 billion in revenue and EPS of $2.70. Sales during the quarter are predicted to arrive at $6.61 billion. The Return on Equity (ROE) value stands at 82.9%. Gilead Sciences's revenue for the quarter was down 9.6% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post $8.88 earnings per share for the current fiscal year. Also, Director John W. Madigan sold 105,000 shares of the stock in a transaction that occurred on Friday, November 18th. This represents a $1.88 dividend on an annualized basis and a yield of 2.46%. The ex-dividend date of this dividend is Tuesday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is presently 18.91%. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company's stock worth $112,000 after buying an additional 500 shares in the last quarter. The stock price recently experienced a 5-day loss of -7.63% with 1.55 average true range (ATR). The high figure known in this time frame is $8.65 with the low being $7.56. The sale was disclosed in a filing with the SEC, which is available through this link. Following the transaction, the insider now owns 3,204,433 shares in the company, valued at approximately $235,814,224.47. BB&T Securities LLC increased its position in shares of Gilead Sciences by 17.4% in the third quarter.

Over the past five trading sessions shares of Zosano Pharma Corporation (NASDAQ:ZSAN) are 71.19%; 68.33% for the month; 248.28% for the last quarter; 53.03% for the past six-months; and -0.5% for the last 12 months.

A number of analysts have recently issued reports on GILD shares. BlackRock Fund Advisors increased its stake in shares of Gilead Sciences by 6.8% in the third quarter. The number of shares now owned by investors are 1.32 bln. Sullivan Bruyette Speros & Blaney LLC increased its stake in Gilead Sciences by 0.6% in the fourth quarter. Given that its average daily volume over the 30 days has been 10.34 million shares a day, this signifies a pretty significant change over the norm. Finally, Albion Financial Group UT increased its stake in Gilead Sciences by 0.6% in the third quarter. Alliancebernstein L.P. now owns 13,346,714 shares of the biopharmaceutical company's stock worth $1,113,383,000 after buying an additional 1,942,138 shares during the period.

Gilead Sciences, Inc.is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need.

To view Vetr's full report, visit Vetr's official website.

Related:

Comments

Other news